Insmed slides as brensocatib HS program halt weighs, despite new Outperform coverage
Insmed shares fell about 3% Friday as investors continued to digest the company’s decision to discontinue its brensocatib hidradenitis suppurativa program after the Phase 2b CEDAR study missed key efficacy endpoints. The pullback comes alongside fresh analyst activity, including Raymond James initiating coverage with an Outperform rating late Thursday.
1. What’s moving the stock today
Insmed (INSM) is trading lower Friday, extending downside pressure after the company said it will discontinue development of brensocatib in hidradenitis suppurativa (HS) following the Phase 2b CEDAR trial failing to meet primary and secondary efficacy endpoints. The decision removed a potential expansion path for brensocatib and has kept near-term sentiment cautious after the initial post-announcement selloff earlier this week. (pl.investing.com)
2. Analyst and positioning cross-currents
The decline is occurring even as Wall Street coverage remains active. Raymond James initiated coverage with an Outperform rating late Thursday/early Friday in published notes, but that supportive development has not been enough to offset the market’s reaction to the HS program exit and associated pipeline de-risking questions. (kr.investing.com)
3. What investors will focus on next
With the HS program now discontinued, investors are refocusing on Insmed’s other upcoming catalysts—especially readouts tied to its respiratory franchise. Insmed has guided that Phase 3 ENCORE topline data for ARIKAYCE in MAC lung disease are anticipated in March or April 2026, keeping the stock sensitive to catalyst timing and expectations. (investor.insmed.com)